Related Experiment Video
Updated: Jul 4, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?
Ekamol Tantisattamo1, Elaine Ku2
1Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine, Orange, CA; Excellent Center for Organ Transplantation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Insights
Intensive blood pressure lowering benefits cardiovascular and kidney health, but evidence is limited in advanced chronic kidney disease (CKD). More research is needed for effective hypertension management in high-risk CKD patients.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hypertension is a modifiable risk factor for cardiovascular disease (CVD) and chronic kidney disease (CKD) progression.
- Intensive blood pressure lowering aims to mitigate cardiorenal risks, but trial data show inconsistencies in advanced kidney dysfunction.
- Current hypertension management for CKD involves evolving therapeutic strategies.
Purpose of the Study:
- To review trial-grade evidence on intensive blood pressure lowering for cardiorenal outcomes in hypertension.
- To discuss the role of various antihypertensive agents in managing hypertension and CKD.
- To highlight the need for further research in patients with advanced CKD.
Main Methods:
- Overview of existing clinical trial data.
- Focus on evidence for intensive blood pressure lowering and antihypertensive agents.
- Analysis of cardiorenal outcomes in patients with varying degrees of kidney dysfunction.
Main Results:
- Intensive blood pressure control shows benefits for cardiorenal outcomes.
- Newer therapies like SGLT2 inhibitors and GLP-1 agonists offer proven benefits but have limited data in advanced CKD.
- Renin-angiotensin system inhibitors remain a cornerstone, but newer agents expand treatment options.
Conclusions:
- Hypertension management is crucial for mitigating cardiorenal risks in CKD patients.
- While newer therapies show promise, their efficacy and safety in advanced CKD require further investigation.
- High-risk patients with advanced CKD may need tailored antihypertensive strategies due to potential adverse effects.
Abstract:
As one of the known modifiable risk factors for cardiovascular disease, hypertension control is an attractive strategy for mitigating the risk of chronic kidney disease progression and cardiovascular disease. However, trial data have not always been consistent in terms of the cardiovascular and kidney benefits of intensive blood pressure lowering in patients with advanced kidney dysfunction. Here, we provide an overview of the trial-grade evidence for intensive blood pressure lowering and the use of different antihypertensive agents to achieve blood pressure control, focusing on cardiorenal outcomes. The evolution of the field from the reliance on renin-angiotensin system inhibition as the first-line agent to control blood pressure to the approval of several newer therapies with proven kidney and cardiovascular benefits including sodium glucose co-transporter 2 inhibitors, nonsteroidal aldosterone antagonists, and glucagon-like peptide-1 agonists has advanced the care of patients with hypertension and CKD. However, evidence for these therapies remains more limited in those with advanced CKD. Further studies are needed in patients with advanced CKD who are at high risk for adverse side effects from antihypertensive therapy.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury IV: Diagnostic Studies and Prevention